Euchrestaflavanone B
Euchrestaflavanone B shows antibacterial activity against Gram positive bacteria, Staphylococcus aureus, Bacillus subtilis and Bacillus cereus. Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of protein kinase CKII activity.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Biochem Biophys Res Commun.2020, 527(4):889-895.
Front Cell Infect Microbiol.2018, 8:292
Mol Med Rep.2014, 9(5):1653-9
Pak J Pharm Sci.2023, 36(1):51-57.
Food and Agriculture Org. Of the UN2019, 151-160
Plants (Basel).2023, 12(22):3877.
Cell Biochem Funct.2018, 36(6):303-311
BMC Complement Med Ther. 2020, 20(1):94.
Plant Sci.2020, 301:110656.
Molecules.2019, 24(21):E3834
Related and Featured Products
Oncol Res. 2005;15(6):327-32.
Inhibition of protein kinase CKII activity by euchrestaflavanone B purified from Cudrania tricuspidata.[Pubmed:
16408697]
METHODS AND RESULTS:
The CKII (EC 2.7.1.37) inhibitory compound was purified from the root barks of Cudrania tricuspidata and identified as (2S)-2-[2,4-dihydroxy-5-(3-methyl-but-2-enyl)-phenyl]-5,7-dihyroxy-6-(3-methyl-but-2-enyl)chroman-4-one (Euchrestaflavanone B). Euchrestaflavanone B was shown to inhibit the phosphotransferase activity of CKII with IC50 of about 78 microM. Steady-state studies revealed that Euchrestaflavanone B acted as a competitive inhibitor with respect to the substrate ATP. A value of 16.4 microM was obtained for the apparent Ki. Concentration of 0.8 microM Euchrestaflavanone B caused 50% growth inhibition of human cancer cells U937 and HeLa. Euchrestaflavanone B-induced cell death was characterized with the cleavage of poly(ADP-ribose) polymerase and procaspase-3, indicating that the inhibitor triggered apoptosis.
CONCLUSIONS:
Because protein kinase CKII is involved in cell proliferation and oncogenesis, these results suggest that Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of CKII activity.
Journal of the Korean Society for Applied Biological Chemistry, 2004,47(2):270-3.
Isolation of Antibacterial Prenylated Flavonoids from Cudrania tricuspidata.[Reference:
WebLink]
METHODS AND RESULTS:
Two prenylated flavonoids were isolated from a chloroform extract of the root bark of Cudrania tricuspidata.
Both compounds (1, 2) showed antibacterial activity against Gram positive bacteria, Staphylococcus aureus, Bacillus subtilis and Bacillus cereus.
CONCLUSIONS:
Their structures were determined as Euchrestaflavanone B (1) and euchrestaflavanone C (2) on the basis of and long-range coupling NMR techniques.
